Skip to main content

Commercializing Discoveries in an Academic Environment

December 17th, 2014 ~ 06:00pm–07:00pm
TMEC 250, Longwood Medical Area

The Harvard Biotech Club will be hosting the first seminar in the series titled Commercializing Discoveries in an Academic Environment, featuring PIs, graduate students, and post-doctoral fellows who are part of startup companies in the biotech sphere.

The event will be held on Wednesday, 12/17, from 6-7pm in TMEC 250 on the Longwood campus. Dinner will be provided.

Please RSVP to the Harvard Biotech Club if you plan on attending.

Our two speakers are Chad Cowan, a founder of CRISPR Therapeutics, and Iain MacLeod, CSO and co-founder of Aldatu Biosciences.


Chad Cowan - Scientific founder, CRISPR Therapeutics

Dr Chad Cowan is an associate professor at Harvard University in the Department of Stem Cell and Regenerative Biology, and at Massachusetts General Hospital, with appointments in the Center for Regenerative Medicine, the Cardiovascular Research Center and the Center for Human Genetics Research. He is an associate member of the Broad Institute and a principal faculty member of the Harvard Stem Cell Institute, where he directs the Diabetes Disease Program and the iPS Cell Core Facility.

Chad has led or been a member of several large efforts to use stem cells to better understand disease, including the National Heart, Lung, and Blood Institute’s Next Gen iPS Cell Project and the Progenitor Cell Biology Consortium. More recently, Chad has focused on using genome editing tools as therapeutics.

Chad received his BA and BS, with honors, from the University of Kansas. He received his PhD from the University of Texas Southwestern at Dallas, garnering the Nominata award for most outstanding thesis. He subsequently completed a Damon Runyon fellowship with Professor Douglas Melton at Harvard University. He was named a Stowers Medical Investigator in 2006 and has been faculty member at Harvard University since 2008.

Iain MacLeod - CSO and Co-Founder of Aldatu Biosciences

Iain is responsible for leading the advancement of Aldatu’s pathogen and drug resistance diagnostic technology in addition to guiding the company’s global health strategy.

He undertook his post-doctoral training at the Harvard School of Public Health, and the Botswana-Harvard AIDS Institute in Gaborone, Botswana, where he focused on HIV drug resistance.

Iain holds a Ph.D. in Pathology – specializing in molecular virology – from the University of Cambridge, an LL.M. in International Law, and a B.Sc. in Virology from the University of Glasgow.

Press Contact

Caroline Perry
(617) 495-4157